Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07659769
NCT07659769RecruitingNot Applicable

Global Healthcare Study on Hidradenitis Suppurativa

Julia Tatjana Maul1 site in 1 country9,600 target enrollmentStarted: January 1, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
9,600
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Detailed Description

The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
14 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Signed General Consent Form, or equivalent document
  • •Confirmed diagnosis of Hidradenitis Suppurativa

Exclusion Criteria

  • •Inability to provide informed consent.
  • •Datasets with ambiguous or unclear diagnosis.

Investigators

Sponsor
Julia Tatjana Maul
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Julia Tatjana Maul

Prof. Dr. med.

University of Zurich

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Real-World Study on the Burden of Hidradenitis Suppurativa
NCT07323303PeriPharm100
Recruiting
Not Applicable
Pelashield™ PainGuard™ vs Restrata® in HS Surgery
NCT07316192Rutgers, The State University of New Jersey10
Completed
Phase 2
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.Hidradenitis Suppurativa
NCT03248531UCB Biopharma SRL90
Recruiting
Not Applicable
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen RepositoryHidradenitis Suppurativa
NCT04115566University of California, San Francisco3,000
Recruiting
Not Applicable
Hidradeinitis suppurativa treated with twice daily dose of oral tofacitinib
CTRI/2025/07/09104621